Covered recipient · General Payments record
BAMIDELE A ADESUNLOYE
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$32,718.16
- Reported across 85 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $6,555.00 | 2 |
| Honoraria | $1,750.00 | 1 |
| Travel and Lodging | $879.72 | 3 |
| Food and Beverage | $351.37 | 10 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| EISAI INC. | $4,630.76 | 7 |
| PFIZER INC. | $2,880.00 | 1 |
| Exelixis Inc. | $1,972.12 | 5 |
| Incyte Corporation | $21.76 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $17.80 | 1 |
| Merck Sharp & Dohme Corporation | $13.65 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $17.80 | 01/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086149863 | CMS |
| Eisai Inc. | $49.69 | 10/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110732686 | CMS |
| Eisai Inc. | $49.69 | 10/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110732688 | CMS |
| Eisai Inc. | $34.03 | 10/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110732690 | CMS |
| Eisai Inc. | $16.33 | 10/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110732692 | CMS |
| Eisai Inc. | $3,675.00 | 12/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1110732694 | CMS |
| Eisai Inc. | $735.00 | 12/18/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1110732696 | CMS |
| Eisai Inc. | $71.02 | 12/18/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1110732698 | CMS |
| Exelixis Inc. | $73.70 | 10/25/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1138555816 | CMS |
| Exelixis Inc. | $28.54 | 10/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138555820 | CMS |
| Exelixis Inc. | $51.38 | 10/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138555822 | CMS |
| Exelixis Inc. | $68.50 | 10/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138555824 | CMS |
| Exelixis Inc. | $1,750.00 | 11/08/2024 | Honoraria | Undisputed | 01/23/2026 | 1138555818 | CMS |
| Incyte Corporation | $21.76 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141229139 | CMS |
| Merck Sharp & Dohme LLC | $13.65 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141745661 | CMS |
| PFIZER INC. | $2,880.00 | 12/31/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1131395959 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.